Pharmaceutical

Armed with Phase III win, Incyte eyes label expansion for Monjuvi

The Phase III inMIND trial evaluating Monjuvi as a combination treatment in relapsed/ refractory follicular lymphoma met its primary endpoint.

Aug 17, 2024 - 04:00
Armed with Phase III win, Incyte eyes label expansion for Monjuvi
The Phase III inMIND trial evaluating Monjuvi as a combination treatment in relapsed/ refractory follicular lymphoma met its primary endpoint.
Read the original article

Tags:

Previous Article

Bavarian Nordic seeks authorisation for mpox vaccine’s use in adolescents

Next Article

Lykos cuts team by 75%, vows to keep MDMA program despite FDA veto

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

FDA approves Amneal’s 505(b)(2) NDA for PEMRYDI RTU

FDA approves Amneal’s 505(b)(2) NDA for PEMRYDI RTU

Jun 15, 2023

STAT+: Biden changes will force health insurers to speed up and get more specific if they want to deny care

STAT+: Biden changes will force health insurers to spee...

Jan 18, 2024

Gene therapy death was caused by an unknown risk of the virus used, study suggests

Gene therapy death was caused by an unknown risk of the...

Sep 28, 2023